Genomic and Therapeutic Landscape of Non-muscle-invasive Bladder Cancer.
Genomic and Therapeutic Landscape of Non-muscle-invasive Bladder Cancer.
Urol Clin North Am. 2020 Feb;47(1):35-46
Authors: Cooley LF, McLaughlin KA, Meeks JJ
Abstract
Non-muscle-invasive bladder cancer (NMIBC) is heterogeneous, but current diagnostic and treatment strategies rely primarily on clinical parameters, lacking individualization to tumor and host genetics and biology. The heterogeneity of NMIBCs is derived from mutations, mutation signatures, chromosomal loss, and disruption of molecular pathways, which ultimately affects tumor progression, recurrence, and responsiveness to intravesical and systemic chemotherapy. Although research is still underway, advances in sequencing technology, insight into differential bacillus Calmette-Guérin responses, and new investigational treatment targets will soon offer clinicians new, precision-based tools to risk stratify and determine treatment regimens for future patients with bladder cancer.
PMID: 31757298 [PubMed - in process]
Source: The Urologic Clinics of North America - Category: Urology & Nephrology Authors: Cooley LF, McLaughlin KA, Meeks JJ Tags: Urol Clin North Am Source Type: research
More News: Biology | Bladder Cancer | Cancer | Cancer & Oncology | Chemotherapy | Genetics | Molecular Biology | Urology & Nephrology